JY
KRYS icon

Jeff Yass’s Krystal Biotech KRYS Stock Holding History

Jeff Yass’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19M Sell
51,000
-12,100
-19% -$3.62M ﹤0.01% 2529
2026
Q1 		$16.3M Buy
63,100
+23,400
+59% +$6.23M ﹤0.01% 2470
2025
Q4 		$9.79M Sell
39,700
-102,800
-72% -$21.6M ﹤0.01% 3068
2025
Q3 		$25.2M Buy
142,500
+23,100
+19% +$3.46M ﹤0.01% 1961
2025
Q2 		$16.4M Buy
119,400
+91,600
+329% +$13.5M ﹤0.01% 2222
2025
Q1 		$5.01M Sell
27,800
-59,400
-68% -$9.99M ﹤0.01% 3645
2024
Q4 		$13.7M Sell
87,200
-35,100
-29% -$6.23M ﹤0.01% 2274
2024
Q3 		$22.3M Buy
122,300
+14,400
+13% +$2.78M ﹤0.01% 1725
2024
Q2 		$19.8M Sell
107,900
-37,100
-26% -$6.23M ﹤0.01% 1741
2024
Q1 		$25.8M Sell
145,000
-10,700
-7% -$1.49M ﹤0.01% 1534
2023
Q4 		$19.3M Buy
155,700
+66,500
+75% +$7.37M ﹤0.01% 1853
2023
Q3 		$10.3M Buy
89,200
+19,300
+28% +$2.35M ﹤0.01% 2523
2023
Q2 		$8.21M Sell
69,900
-1,300
-2% -$133K ﹤0.01% 2772
2023
Q1 		$5.7M Buy
71,200
+49,400
+227% +$3.88M ﹤0.01% 3258
2022
Q4 		$1.73M Sell
21,800
-3,500
-14% -$260K ﹤0.01% 4996
2022
Q3 		$1.76M Buy
25,300
+7,700
+44% +$556K ﹤0.01% 5187
2022
Q2 		$1.16M Buy
17,600
+1,600
+10% +$99.5K ﹤0.01% 6166
2022
Q1 		$1.06M Sell
16,000
-24,300
-60% -$1.52M ﹤0.01% 6950
2021
Q4 		$2.82M Buy
40,300
+28,500
+242% +$1.66M ﹤0.01% 4757
2021
Q3 		$616K Sell
11,800
-52,400
-82% -$3.1M ﹤0.01% 8854
2021
Q2 		$4.37M Buy
64,200
+61,600
+2,369% +$4.3M ﹤0.01% 4275
2021
Q1 		$200K Buy
+2,600
New +$189K ﹤0.01% 11423
2020
Q4 		– Sell
-24,400
Closed -$1.05M – 11407
2020
Q3 		$1.05M Sell
24,400
-2,100
-8% -$91.2K ﹤0.01% 5999
2020
Q2 		$1.1M Buy
+26,500
New +$1.27M ﹤0.01% 5704

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Jeff Yass's KRYS Position: Q2 2026 in Review

Jeff Yass reduced its Krystal Biotech (KRYS) stake by 79% in Q2 2026, selling an estimated $2.13M and leaving 1,899 shares worth $706K. The position accounts for ﹤0.01% of the portfolio, ranked #9082.

Jeff Yass first reported a position in KRYS in Q4 2018 and has held it in 29 quarters since. The position peaked at $18.1M in Q1 2024. 421 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Jeff Yass held 1,899 shares of Krystal Biotech worth $706K as of Q2 2026.
  • Jeff Yass sold 7,143 Krystal Biotech shares in Q2 2026, an estimated $2.13M.
  • Krystal Biotech made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #9082 holding.
  • Jeff Yass first reported a position in Krystal Biotech in Q4 2018 and has held it in 29 quarters since.
  • Jeff Yass's Krystal Biotech position peaked at $18.1M in Q1 2024.
  • 421 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.